In addition, pharmacological inhibition of Sphk2 results in anti-inflammatory effects in a number of murine disease models including ulcerative colitis [32], Crohn’s disease [33] and inflammatory arthritis [34], implying that reduced Sphk2 activity attenuates inflammation and injury in agreement with our findings. Here, SPHK2 is linked to glycogen storage disease VI.